Aspect Biosystems
PrivateLast Round
Grant
Apr 2, 2026
Total Funding Raised
$192.73M
Company Overview
Aspect Biosystems is a Canadian biotechnology company that is developing bioprinted tissue therapeutics to treat diseases. The company's proprietary platform uses microfluidic 3D bioprinting technology to create living human tissues for medical research and therapeutic products. This full-stack tissue therapeutic platform integrates AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials. Aspect Biosystems aims to create implantable tissues that can replace, repair, or supplement biological functions inside the body, with a focus on metabolic and endocrine diseases such as Type 1 diabetes and liver disorders. The company was founded in 2013 out of the University of British Columbia and is headquartered in Vancouver, Canada.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, 3D Printing, Medical AI, Advanced Materials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aspect Biosystems Comps
Public and private peers based on sector, stage, and business model.
Aspect Biosystems Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 2, 2026 | ||||
| Series B | Jan 8, 2025 | ||||
| Grant | Jul 10, 2024 | ||||
| Grant | Mar 20, 2023 | ||||
| Series A | Jan 9, 2020 | ||||
Grant | Nov 15, 2018 |
Key People
Founding team and executive leadership
Aspect Biosystems Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InBC Investment Corp. | Series B |
| Genome British Columbia | VC Round |
| Government of British Columbia | Grant |
| Government of Canada | Grant |
| Endure Capital | VC Round |
| T1D Fund | Series B |
| Dimension | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
$57M grant funding secured.
- Jan 23, 2026
Will develop therapies based on stem cell-derived islets.
Aspect Biosystems Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aspect Biosystems's valuation, stock price, and market status.
